Abstracts

Reliable Genotypic Tropism Tests for the Major HIV-1 Subtypes

Background: The major obstacles to the CCR5-antagonist maraviroc being more widely used in anti-HIV-1 therapy regimens are (i) traditional pre-treatment phenotypic tropism tests to determine virus susceptibility to maraviroc are expensive and time consuming, and (ii) cheaper and more rapid genotypic tropism tests have been developed primarily for HIV-1 subtype B strains, which account for…

Accuracy of Re-Reading HIV Rapid Tests and the Effect of Prolonged High Temperature

Background: Accurate rapid diagnostic test (RDT) results are critical to HIV testing, care and prevention services. However, suboptimal storage at ambient temperatures above manufacturer-recommendation is common in sub-Saharan Africa. Re-reading of used test kits can provide valuable programmatic quality-assurance, and “late” reading is also commonly reported following HIV self-testing. We evaluated the effects of prolonged…

4′-Ethynyl-2-Fluoro-2′-Deoxyadenosine (EFdA) Has an Extremely High Genetic Barrier, Persistently Exerting Highly Potent Activity Against a Variety of HIV-1 Isolates Including EFdA-Selected HIV-1 Variants

Background: 4′-Ethynyl-2-fluoro-2′-deoxyadenosine (EFdA), a nucleoside reverse transcriptase inhibitor (NRTI), exerts potent activity against a wide spectrum of HIV-1 variants, including multi-drug-resistant HIV-1 isolates. EFdA is currently under clinical trials in the US as a peroral QD-possible therapeutic against HIV-1 infection and AIDS. We have recently selected in vitro HIV-1 variants resistant against EFdA (HIV-1EFdA-R), carrying…

GSK2838232, a Second Generation HIV-1 Maturation Inhibitor With an Optimized Virology Profile

Background: The first generation HIV-1 maturation inhibitor bevirimat demonstrated clinical efficacy in infected subjects. However, gag polymorphisms in both capsid (p24) and Sp1 regions were liabilities for bevirimat potency against a broad range of HIV-1 isolates; therefore limiting the clinical utility of bevirimat to 40% of HIV patients without polymorphisms in the 369-370 region of…

BMS-986001: A Promising Candidate for HIV-2 Treatment

Background: New antiretrovirals (ARV) are urgently needed for the treatment of HIV-2 infection. BMS-986001 is an investigational NRTI that potently suppresses HIV-1 replication in culture and maintains full or partial activity against NRTI-resistant HIV-1 mutants. To examine the potential utility of the drug in HIV-2–infected individuals, we compared the susceptibilities of wild-type HIV-1 and HIV-2…

Dual Loaded Sustained Release Core-Shell Nanoparticles for Anti-HIV Therapy

Background: Human immunodeficiency virus (HIV) is the world’s deadliest infectious disease and progressively suppresses the immune system leading to mortality. Due to length of treatment, high pill burden and adverse effects, patient non-adherence often occurs resulting in viral resistance to current therapeutic regimens. Biodegradable poly(lactic-co-glycolic acid (PLGA) nanoparticles (NPs) are able to control the release…

Chemical Facilitated Endosomal Storage of Long-Acting Antiretroviral Nanoparticles

Background: Suboptimal adherence to antiretroviral therapy (ART) for HIV-1 begets viral mutations and drug resistance. This might be reduced or eliminated by maintenance of plasma and tissue drug levels above an effective dose for prolonged time periods after single dose administration. To achieve this, we sought pharmacologic approaches that would augment ART depots in intracellular…